BioPharmSignal logoBioPharmSignal

Biotech News

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders

C4 Therapeutics (CCCC)C4 TherapeuticsCompany update

DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage

Related news

CCCCC4 Therapeutics2026-11-03 12:00 EST

C4 Therapeutics to Participate in Upcoming November Investor Conferences

CCCCC4 Therapeutics2026-11-02 21:01 EST

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-09-29 09:15 EST

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

ELVNEnliven Therapeutics2026-10-06 20:05 EST

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

KPTIKaryopharm Therapeutics2026-11-02 12:10 EST

Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future

View all latest news

C4 Therapeutics

Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins. Cemsidomide Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma. Combination Strategy Clinical...

Recent company news

CCCCC4 Therapeutics2026-11-03 12:00 EST

C4 Therapeutics to Participate in Upcoming November Investor Conferences

CCCCC4 Therapeutics2026-11-02 21:01 EST

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCCC4 Therapeutics2026-10-29 11:00 EST

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders

CCCCC4 Therapeutics2026-09-25 11:00 EST

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

CCCCC4 Therapeutics2026-09-03 11:00 EST

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

Stock data

Close
2.95 USD
Market cap
479.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States